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Oxalate stimulates IL-6 production in HK-2 cells, a line of
human renal proximal tubular epithelial cells
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Oxalate stimulates IL-6 production in HK-2 cells, a line of hu-
man renal proximal tubular epithelial cells.
Background. Oxalate is a metabolic end product excreted
primarily by the kidney and associated with several pathologic
conditions. The most common pathologic condition involving
oxalate is the formation of calcium oxalate stones in the kid-
ney. Several stimuli have been implicated in the development
of glomerular and tubular injury in various forms of immune-
mediated renal diseases. The elevated level of interleukin-6
(IL-6) has been reported in the urine of kidney stone–forming
patients. In the present study, we investigated the role of oxalate,
a major constituent of calcium oxalate kidney stone disease, in
the production of IL-6 in normal human HK-2 kidney cells.
Methods. Confluent cultures of HK-2 cells (a renal ep-
ithelial cell line of human origin) were exposed to various
concentrations of oxalate (0.2 to 2.0 mmol/L) and lipopolysac-
charide (LPS) (0.1 and 10 lg/mL) for various time points
(4–24 h) under serum-free conditions. The conditioned medi-
ums were collected, and an IL-6 protein level was measured
by enzyme-linked immunosorbent assay (ELISA). The total
cellular RNA was isolated from the cells and subjected to
relative quantitative reverse transcription-polymerase chain re-
action (RT-PCR) to determine the expression of IL-6 mRNA.
The statistical analysis of the results was carried out using the
Student t test.
Results. HK-2 cells express IL-6 mRNA and protein. Ox-
alate increased the secretion of IL-6 protein in HK-2 cells in
a concentration-dependent fashion. Oxalate exposure to HK-2
cells also induced transcriptional up-regulation of the IL-6 gene,
as determined by the increased level of IL-6 mRNA expres-
sion following treatment with oxalate. Moreover, the effects
of oxalate on IL-6 expression were time- and concentration-
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dependent. This is the first report demonstrating the regulation
of IL-6 by oxalate.
Conclusion. This study provides the first direct evidence that
oxalate up-regulates the expression and secretion of IL-6 in re-
nal epithelial cells. The increased IL-6 expression and secretion
by renal epithelial cells may play a critical role in the progression
of urolithiasis in hyperoxaluric conditions.
Oxalate, a metabolic end product, is excreted primarily
by the kidney and is associated with several pathologic
conditions. This organic dicarboxylate is freely filtered
at the glomerulus and undergoes bidirectional transport
in the renal tubules [1–3]. The most common pathologic
condition involving oxalate is the formation of calcium
oxalate stones in the kidney [4]. Besides renal stone
formation, oxalate deposits are also associated with hy-
perplasic thyroid glands, benign neoplasm of the breast,
renal cysts in acquired renal cystic disease, and prolifer-
ating cells in the kidney [5–8]. Many of these conditions
are associated with aberrant cell proliferation and cell
death. Previous studies from our laboratory and those of
others have demonstrated that oxalate interaction with
renal epithelial cells results in a program of events, selec-
tive activation of signaling pathways, reinitiation of DNA
synthesis, cell growth, and apoptosis [9–17]. These con-
siderations suggest that oxalate toxicity could result in
tissue damage and inflammation.
Several chemotactic factors and adhesion molecules
play key roles in the proinflammatory/inflammatory re-
action at various sites throughout the body, includ-
ing the kidney [18]. Cytokines perform ever-increasing
roles in both the regulation of general homeostasis, and
in orchestrating the immune response during disease.
Various cascades of mediator systems can be activated
following initial injury or stimulation of the proximal
tubular cells, to enhanced local production of comple-
ment, chemokines, cytokines, and matrix components.
Renal tubular cells have been shown to express vari-
ous cytokines and other mediators of inflammatory re-
sponse [19]. Interleukin-6 (IL-6), which was originally
identified as a B-cell differentiation factor, is now known
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to be a multifunctional cytokine that regulates the im-
mune response, hematopoiesis, the acute-phase response,
and inflammation [20]. An increased production of IL-6
from mesangial and proximal tubular epithelial cells has
been shown in vitro in response to many diverse stim-
uli, including interleukin 1 (IL-1), tumor necrosis factor
alpha (TNF-a), and lipopolysaccharide (LPS) [21, 22]. El-
evation in urinary IL-6 has been noted in disease states
such as interstitial cystitis, mesangial glomerulonephri-
tis, and urinary tract infections [23–25]. IL-6 may also
function indirectly as a mediator of inflammation, which
may act along with other mediators such as IL-1, TNF-
a, and LPS in the acute inflammatory response [26].
The elevated levels of IL-6 have been reported in the
urine of kidney stone–forming patients [27]. The inflam-
mation following oxalate-induced injury plays a signifi-
cant role in the pathogenesis of nephrolithiasis, but the
molecular mechanism/s and mediators of this proinflam-
matory/inflammatory response in the interstitium are not
delineated.
In the present study, we investigated the role of oxalate,
a major constituent of calcium oxalate kidney stone dis-
ease, on IL-6 gene expression and protein production in
HK-2 cells, a line of proximal tubular epithelial cells from
normal human kidney. Our findings provide evidence that
IL-6 gene expression and protein production increases in
oxalate-exposed HK-2 cells, which may have a critical
role in the progression of the hyperoxaluric condition of
urolithiasis disease.
METHODS
Materials
HK-2 cells (CRL-2190), a line of renal proximal tubu-
lar epithelial cells of human origin, were obtained from
the American Type Culture Collection (Manassas, VA,
USA). Penicillin and streptomycin antibiotic mixture,
Dulbecco’s modified Eagle’s medium (DMEM), and heat
inactivated fetal bovine serum (FBS) were obtained from
Invitrogen (Carlsbad, CA, USA). LPS was obtained from
EMD Biosciences, Inc. (San Diego, CA, USA). Human
IL-6 ELISA kit was purchased from ALPCO Diagnostics
(Windham, NH, USA). Human IL-6 gene specific rela-
tive quantitative reverse transcription-polymerase chain
reaction (RT-PCR) kit was purchased from Ambion
(Austin, TX, USA). All other chemicals were of analyt-
ical grade, and were purchased from Sigma (St. Louis,
MO, USA).
Cell culture
HK-2 cells (American Type Culture Collection) were
grown on polystyrene T-75 flasks. The cells were serially
passaged and maintained in high glucose DMEM, 4.5 g/L
glucose supplemented with 10% heat-inactivated fetal
bovine serum (FBS), penicillin (100 U/mL), and strep-
tomycin (100 lg/mL) antibiotic mixture at 37◦C under
5% CO2/95% air. For experiments, cells were grown in 6-
well plates. Stock solution of sodium oxalate (20 mmol/L)
was prepared in phosphate-buffered saline (PBS), pH ad-
justed to 7.4 and used within 2 to 3 days. Where indi-
cated, sodium oxalate was added at a final concentration
of 0.2, 0.8, 1.0, or 2.0 mmol/L (total), which increased the
free oxalate levels to 0.07, 0.28, 0.35, or 0.75 mmol/L, re-
spectively. Estimates of free oxalate were obtained using
EQUIL program.
Assay for interleukin-6
The human IL-6 assay was performed by using solid-
phase enzyme-linked immunosorbent assay (ELISA) ac-
cording to the manufacturer’s recommended protocol
(ALPCO Diagnostics). Briefly, cells were grown to con-
fluence in 6-well plates. Serum-starved (12–18 h) cells
were exposed for various concentrations of oxalate (0.2–
2.0 mmol/L) or LPS (0.1 and 10 lg/mL) for 24 hours. At
the end of experimental period, the conditioned medium
were collected and centrifuged for 5 minutes at 5000 rpm
to remove cell debris. One hundred mL of cultured me-
dia from treated cells with oxalate, LPS, or IL-6 standard
were added in duplicates to the precoated wells with mon-
oclonal antibodies specific for IL-6. Then, 150 mL of IL-6
calibrator/sample diluents was added to every well and
the plate was rotated for 2 hours at room temperature on a
plate mixer (350–400 rpm). The nonreactive sample com-
ponents were removed by washing 4 times with 300 mL
wash buffer. Afterward, a second polyclonal horseradish
peroxidase-labeled anti-IL-6 antibody (200 mL/well) was
added, and the plate was rotated for an additional 2
hours, as mentioned above. An excess of enzyme con-
jugate was washed 4 times with 300 mL washing buffer.
Following washing, 200 mL of chromogenic substrate so-
lution, 3,3,5,5-tetra-methyl-benzidine (TMB), was added
to all wells for 30 minutes at room temperature, and
the reaction was stopped by the dispensing of 50 mL
of 2 mol/L hydrochloric acid. The optical density of the
color solution was measured at 450 nm using EL340 Mi-
croplate BiotekTM biokinetics reader (Biotek, Winooski,
VT, USA). Prior to ELISA, the total protein content of
the cultured media from treated and untreated groups
was determined using BCA Protein Assay Kit (Pierce,
Rockford, IL, USA).
RNA preparation and first-strand cDNA synthesis
Total RNA was isolated according to the guanidium
thiocyanate-phenol-chloroform extraction method [28].
HK-2 cells were grown to confluence in 6-well plates.
Serum-starved (12–18 h) cells were exposed for various
concentrations of oxalate (0.1, 1.5, and 2.0 mmol/L) for
4 hours, or 1 mmol/L oxalate for various time points (4–
24 h). The RNA concentration was measured by spec-
trophotometric absorbance at 260 nm. The total RNA
was treated with RQ1 RNase-Free DNase (Promega,
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Madison, WI, USA) to maintain the integrity of the
RNA, and first-strand cDNA was synthesized by using
Moloney Murine Leukemia Virus Reverse Transcrip-
tase kit (M-MLV RT), according to the manufacturer’s
recommended protocol (Gibco BRL, Life Technologies,
Gaithersburg, MD, USA). Briefly, 5 lg total RNA treated
with RNase-Free DNase was reverse-transcribed for 60
minutes at 37◦C using 1 lL (200 U) M-MLVRT in the
presence of 250 ng random hexamer (Promega), 1 lL
of 10 mmol/L dNTP mix, 4 lL of 5X first-strand buffer
[250 mmol/L Tris-HCl (pH 8.3), 375 mmol/L KCl, 15
mmol/L MgCl2], 2 lL of 0.1 mol/L dithiothreitol (DTT),
1 lL of RNaseOUT recombinant ribonuclease inhibitor
(40 U/lL), and 1 lL of 10 mmol/L dNTP mix in 20 lL
final volume.
IL-6 relative quantitative RT-PCR
IL-6 PCR reactions were carried out with a hu-
man IL-6 gene-specific relative quantitative RT-PCR
(Ambion). PCR amplification was carried out by using
specific oligonucleotide primers selected within the cod-
ing regions of the genes. IL-6 primers were designed to
produce a 242-bp product, and 18s primers were designed
to produce a 495-bp product. PCRs were composed of 5
lL of cDNA template, 100 ng each of sense and anti-
sense oligonucleotide primers, 2.5 lL of optimized Taq
PCR buffer (Promega), 0.4 mmol/L dNTP mixture, and 2
U of Taq polymerase in a total reaction volume of 25 lL.
Following an initial 5-minute incubation at 94◦C, PCRs
were performed using a 45-second denaturation step at
94◦C, followed by a 1-minute annealing step at 57◦C, and
a 2-minute elongation step at 72.0◦C. A total number of 30
PCR cycles were carried out for the detection of IL-6 and
18s RNA, followed by a final elongation reaction for 10
minute at 72.0◦C. PCR products were separated by elec-
trophoresis at 80 V for 60 minutes through a 2% agarose
gel, and were detected by ethidium bromide staining. Ex-
pected sizes of specific PCR products (495 and 242 bp for
18s and IL-6, respectively) were verified by reference to
a 100-bp DNA ladder.
Measurement of free radical production
Oxalate-induced changes in the reduction of Nitro blue
tetrazolium (NBT), a dye that reacts with superoxide,
were used to evaluate oxidant stress as described previ-
ously [17]. For these experiments, confluent HK-2 cells
grown in 12-well plates were exposed, for varying peri-
ods (0 to 180 min), to DMEM containing 25 lg/mL NBT.
Where indicated, oxalate was also added alone or in com-
bination with SOD or catalase. At the predetermined
intervals (0, 60, 120, or 180 min), the medium was re-
moved and the reaction was halted by the addition of 70%
methanol. The monolayers were washed with 4 changes of
100% methanol to remove the unreduced NBT, air dried,
and solubilized with a mixture of 2M KOH and dimethyl
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Fig. 1. Oxalate and lipopolysaccharide (LPS) stimulate interleukin-6
(IL-6) production from HK-2 cells. Confluent, growth-arrested, and
serum-starved HK-2 cells were exposed to oxalate (1 mmol/L) or LPS
(0.1, and 10 lg/mL) for 24 hours. The conditioned mediums were col-
lected and assayed for IL-6 by ELISA, as described in Methods. The
IL-6 levels were expressed as pg/mL, and each value represents the
mean ± SD of at least 3 to 5 experiments, each performed in duplicate.
The star indicates a significant difference (P < 0.001, Student t test).
sulfoxide (DMSO) in a ratio of 1:1.167 (v/v). Samples
were then centrifuged for 4 minutes at 15,000 rpm, and
supernatants were read at 700 nm (density OD700) us-
ing a Beckman DU-650 spectrophotometer (Beckman-
Coulter, Fullerton, CA, USA) against a blank containing
KOH and DMSO.
Statistical analysis
For analysis of the data, an unpaired Student t test was
used for statistical significance. Results are expressed as
the mean ± SD, and P < 0.001 was deemed significant.
RESULTS
Oxalate and LPS stimulate IL-6 secretion from HK-2
cells
For these studies, confluent, growth-arrested, and
serum-starved HK-2 cells were exposed to DMEM alone,
or in combination with oxalate (1 mmol/L) or LPS (0.1
and 10 lg/mL) for 24 hours. At the end of experimen-
tal periods, the cultured conditioned mediums were col-
lected, and their IL-6 levels were measured by ELISA.
As can be seen from Figure 1, the secretion level of IL-6
in oxalate-exposed HK-2 cells, as compared to untreated
control cells, was significantly elevated (602 ± 70 vs. 97 ±
12 pg/mL, P < 0.001). LPS is known to induce expres-
sion of a number of genes, including IL-6; we observed
that even a low dose of LPS (0.1 lg/mL) exposed HK-2
cells significantly increases the level of secretion of IL-6
compared to untreated control (467 ± 50 vs. 97 ± 12 pg/
mL, P < 0.001, Fig. 1). The higher dose of LPS (10 lg/mL)
secreted a very high level of IL-6 (1204 ± 130 pg/mL).
These results demonstrate that oxalate exposure results
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Fig. 2. Oxalate stimulates dose-dependent increases in interleukin-6
(IL-6) production from HK-2 cells. Confluent, growth-arrested, and
serum-starved HK-2 cells were exposed to oxalate (0.2 to 2.0) for 24
hours. The conditioned mediums were collected and assayed for IL-6
by ELISA, as described in Methods. The IL-6 levels were expressed as
pg/mL, and each value represents the mean ± SD of at least 3 to 5 ex-
periments, each performed in duplicate. The star indicates a significant
difference (P < 0.001, Student t test).
in elevated secretion of IL-6. Moreover, oxalate-
stimulated IL-6 secretion was comparable to that of LPS,
a known inducer of IL-6.
Oxalate stimulates IL-6 secretion in a dose-dependent
manner from HK-2 cells
For these studies, confluent, growth-arrested, and
serum-starved HK-2 cells were exposed to DMEM alone,
or in combination with varying concentrations of oxalate
(0.2–2.0 mmol/L) for 24 hours. At the end of experimen-
tal periods, the conditioned mediums were collected, and
their IL-6 levels were measured by ELISA. Results pre-
sented in Figure 2 show that oxalate stimulated secretion
of IL-6 in a dose-dependent fashion at all the concentra-
tions tested (0.2–2.0 mmol/L).
Oxalate increases IL-6 mRNA expression in a
time-dependent manner
For these studies, confluent, growth-arrested, and
serum-starved HK-2 cells were exposed to DMEM alone,
or in combination with oxalate (1.0 mmol/L) for 4 to 24
hours. At the end of experimental periods, total cellular
RNA was isolated from the cells and subjected to rela-
tive quantitative RT-PCR to determine the expression of
IL-6 and 18s mRNA. As can be seen from Figure 3A, the
expression of IL-6 mRNA was significantly elevated in
oxalate-exposed HK-2 cells compared to untreated con-
trol cells in a time-dependent manner. Maximum stimu-
lation of IL-6 mRNA expression was observed at about
4 to 6 hours of oxalate exposure, with an average 1.8-
fold increase (Fig. 3B). However, there was no significant
change in the expression level of 18s mRNA (internal
control) following HK-2 cells exposed to oxalate
(Fig. 3A). These results demonstrate that oxalate expo-
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Fig. 3. Oxalate exposure increases time-dependent increase in
interleukin-6 (IL-6) mRNA in HK-2 cells. Confluent, growth-arrested,
and serum-starved HK-2 cells were exposed to oxalate (1.0 mmol/L) for
various time points (4, 6, and 24 h). Total RNA was isolated according to
the guanidium thiocyanate-phenol-chloroform extraction method, and
the human IL-6 gene-specific relative quantitative RT-PCR was carried
out as described in Methods. (A) Representative relative quantitative
RT-PCR results for IL-6 and 18s ribosomal mRNA. (B) Relative IL-6
mRNA levels of HK-2 cells treated with oxalate (1 mmol/L) for various
time points. The values were obtained by dividing the densitometric
reading of the IL-6 band by that of the 18s band.
sure increases expression of IL-6 in a time-dependent
fashion.
Oxalate increases IL-6 mRNA expression in a
dose-dependent manner
For these studies, confluent, growth-arrested, and
serum-starved HK-2 cells were exposed to DMEM alone,
or in combination with oxalate (1.0–2.0 mmol/L) for
4 hours. At the end of experimental periods, total cellular
RNA was isolated from the cells and subjected to relative
quantitative RT-PCR to determine the expression of IL-6
and 18s mRNA. As can be seen from the Figure 4A, the
expression of IL-6 mRNA in oxalate-exposed HK-2 cells,
compared to untreated control cells, was significantly el-
evated, in a dose-dependent manner. Maximum expres-
sion of IL-6 mRNA can be seen at 2.0 mmol/L oxalate
(Fig. 4B). However, there was no significant change in the
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Fig. 4. Oxalate exposure increases dose-dependent increase in
interleukin-6 (IL-6) RNA in HK-2 cells. Confluent, growth-arrested,
and serum-starved HK-2 cells were exposed to various concentrations
of oxalate (1.0 to 2.0 mmol/L) for 4 hours. Total RNA was isolated
according to the guanidium thiocyanate-phenol-chloroform extraction
method, and human IL-6 gene specific relative quantitative RT-PCR
was carried out as described in Methods. (A) Representative relative
quantitative RT-PCR results for IL-6 and 18s ribosomal mRNA. (B)
Relative IL-6 mRNA levels of HK-2 cells treated with various concen-
trations of oxalate (1.0 to 2.0 mmol/L) for 4 hours. The values were
obtained by dividing the densitometric reading of the IL-6 band by that
of the 18s band. ∗Indicates a significant difference compared to control
(P < 0.001, Student t test).
expression level of 18s mRNA (internal control) follow-
ing HK-2 cells exposed to oxalate (Fig. 4A). These results
demonstrate that IL-6 mRNA expression is increased by
oxalate in a dose-dependent manner.
Oxalate-induced superoxide production is necessary for
IL-6 expression
Previous studies from our laboratory have shown that
oxalate exposure to HK-2 cells resulted in superoxide
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Fig. 5. Oxalate-induced IL-6 expression is mediated in part by free
radical production. Effect of pretreatment with SOD on free-radical
production: For these experiments, confluent monolayers of HK-2 cells
were exposed to DMEM containing 25 lg/mL NBT plus varying oxalate
(0 or 1 mmol/L total), alone or in the presence of SOD. ∗Indicates a
significant difference compared to control (P < 0.005, Student t test).
a, Indicates a significant difference compared to oxalate treated group
(P < 0.005, Student t test).
production [17]. These data presented in Figure 5 indi-
cate that oxalate exposure produces a time-dependent
increase in the accumulation of reduced NBT dye,
demonstrating increased superoxide production. The
addition of superoxide dismutase (SOD) suppressed
oxalate-stimulated free radical production. We also ob-
served that the pretreatment with SOD of HK-2 cells re-
sulted in the inhibition of IL-6 expression (Fig. 5B). Taken
together, these data demonstrate that oxalate-stimulated
IL-6 expression is mediated, at least in part, by free-
radical production.
DISCUSSION
The present study provides evidence that human renal
epithelial cells (HK-2 cells) express IL-6 mRNA and pro-
tein, and the oxalate exposure of these cells resulted in a
significant alteration at the transcription and translation
levels (Figs. 1–4). These findings are significant because
elevation of IL-6 has been shown in the urine samples of
kidney stone–forming patients [27]. The increased pro-
duction of IL-6 may have a crucial role in the pathogene-
sis and physiopathology of urolithiasis. IL-6 is produced
by a wide variety of cell types in response to many differ-
ent stimuli, including TNF-a, LPS, and IL-1 [29]. We also
observed that LPS-exposed HK-2 cells produce a very
high level of IL-6 (Fig. 1). It is a typical cytokine, exhibit-
ing functional pleiotropy, and involved in the immune
response, inflammation, and hematopoiesis [18].
In the past few decades, accumulating evidence has
been generated on the central role of the proximal tubular
cell in renal injury and dysfunction, such as can be found
in some patients with glomerular proteinuria, in chronic
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Fig. 6. Effect of SOD on IL-6 expression. Confluent, growth-arrested,
and serum-starved HK-2 cells were exposed to oxalate (0 to 2.0) alone
or in combination with SOD for 24 hours. The conditioned mediums
were collected and assayed for IL-6 by ELISA, as described in Methods.
The IL-6 levels were expressed as pg/mL, and each value represents the
mean ± SD of at least 3 experiments, each performed in duplicate.
a, Indicates a significant difference compared to control (P < 0.001,
Student t test). ∗∗Indicates a significant difference compared to oxalate
treated group (P < 0.001, Student t test).
renal rejection, or following ischemic insult. Following
initial injury or stimulation of the proximal tubular cells,
various cascades of mediator systems can be activated,
leading, for example, to enhanced local production of
complement, chemokines, cytokines, and matrix compo-
nents. The locally produced mediators can subsequently
lead to the amplification of injury—either directly or
indirectly—by the enhancement of an influx of proin-
flammatory cells, such as macrophages, polymorphonu-
clear leukocytes, and T cells. The concerted production
of cytokines and chemokines may tip the balance to a
more proinflammatory pathway, leading to irreversible
interstitial injury of the kidney and loss of renal function
[18].
Within the kidney, elevated levels of IL-6 have been
demonstrated in both resident and infiltrating cells in var-
ious forms of glomerulonephritis and tubulointerstitial
nephritis, and, indeed, have been suggested to contribute
to the pathogenesis or progression of the disease [30].
An elevated level of IL-6 has been reported in urolithi-
asis patients. IL-6 is also elevated in bacterial cystitis.
The pattern of cytokine elevation in bacterial cystitis is
quite different from the pattern observed in urolithia-
sis. In urolithiasis, only IL-6 was found to be elevated in
the urine sample of the patients, while in bacterial cysti-
tis, marked elevations in IL-1 beta, IL-1 alpha, and IL-6
were observed [27]. Bladder epithelium has been shown
to produce IL-6 in response to various agents, and IL-
6 has been proposed as a potential marker for intersti-
tial cystitis. In the kidney, IL-6 elevation is produced by
mesangial cells [31, 32]. A potential involvement of IL-6
in epithelial cell growth and differentiation has been pro-
posed [33]. It was suggested that IL-6 in stone disease is
unlikely to be derived from leukocytes; epithelial cells or
other cells may possibly contribute to the production of
IL-6. Our findings directly demonstrate that oxalate, the
major constituent of calcium oxalate kidney stones, stim-
ulates IL-6 secretion, which suggests that inflamed renal
epithelial cells directly secrete IL-6 during calcium ox-
alate kidney stone pathogenesis. It is important to point
out here that the results of our study may be relevant
only to stone patients showing elevated urinary oxalate
excretion. Indeed, other studies have suggested lack of
inflammation and or tubular damage in idiopathic stone
formers. Nonetheless, two subgroups of patients that have
been shown to have elevated hyperoxaluria and proximal
tubular damage and or inflammation are the patients with
primary hyperoxaluria, and patients suffering from stone
disease following intestinal bypass surgery [34].
Our studies presented herein demonstrate that
oxalate-stimulated IL-6 expression and secretion could
be inhibited by the free-radical scavenging agent (SOD).
The results indicate that oxalate-associated free-radical
production was at least in part necessary for IL-6 secre-
tion and synthesis. These data suggest a role for oxidative
stress in oxalate-stimulated IL-6 expression.
The mechanism/s that elicit the IL-6 release in renal
cells are unclear, and the biologic role for IL-6—after
its release from renal cells—is uncertain. The pathogen-
esis which gives rise to IL-6 elevation in urolithiasis is
uncertain. There are two alternate scenarios to explain
the elevation of IL-6. IL-6 may be released after stone
formation, upon the mechanical stimulation (irritation)
of epithelial cells [35], or it may be a contributor to the
formation of stones. The possibility of a complex inter-
action between epithelial cells, the stone itself, and other
cells may be needed for IL-6 production to occur. Alter-
nately, IL-6 is known to cause bone resorption, and thus,
elevated serum calcium levels [36]. Stone formers with
idiopathic hypercalciuria have decreased bone mineral
density [37, 38]. Our studies strongly suggest increased
urinary oxalate as a contributor to increased IL-6 in idio-
pathic stone formers. However, it is not clear that in vivo
IL-6 secreted by renal cells is capable of entering circu-
lation. Whether IL-6 derived from nascent stone disease
may contribute to bone resorption and stone formation
remains unclear, and requires further study.
CONCLUSION
IL-6 is elevated in oxalate-exposed human renal ep-
ithelial cells at the transcriptional and translational
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levels. These data suggest that oxalate-induced IL-6 pro-
duction by the renal epithelium may play a critical role in
the initiation/progression of urolithiasis. With idiopathic
calcium oxalate urolithiasis likely being a multifactorial
disease, it is unlikely any one cause of this disease can
be found. Additionally, the biologic role of physiologic
processes can be difficult to discern from in vitro studies
because local cell death could be beneficial or detrimental
in regards to crystalluria and stone formation. The thresh-
old for oxalate-induced IL-6 expression in HK-2 cells is
much higher than these cells commonly experience un-
der normal physiologic conditions. The IL-6 production
may reflect urothelium changes following oxalate injury
and, as such, this may be appropriate only in subgroups
of patients suffering from higher levels of urinary oxalate
(i.e., PH-1 and intestinal bypass patients, and maybe some
idiopathic hyperoxaluric patients).
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